NVO: Oversold, But I’m Staying PatientYes, NVO has pulled back hard — from highs near $148 to the mid-$60s, now trading around $68.33. While this selloff may look oversold on many levels, I’m still avoiding the stock for now.
The broader market remains in a downtrend, and with macro uncertainty still front and center, I’m not eager to
Key facts today
On April 16, 2025, President Trump signed an order extending Medicare's drug pricing negotiations for Novo Nordisk's Ozempic and Wegovy from 9 to 13 years, potentially maintaining premium prices.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
65.43 MXN
291.41 B MXN
837.97 B MXN
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
NVO, Rhyming with historical golden buy zoneUsing the Guassian Channel indicator on the monthly timeframe. We can see that in the past, after the price has significantly correct from its ATH of 50%+, price tend to reverse at the lower channel support(2times on chart) or at the upper support line ( 1 time on the chart)
Right now we are curre
3/27/25 - $nvo - obvious at $70... 10% size3/27/25 :: VROCKSTAR :: NYSE:NVO
obvious at $70... 10% size
- at btc conf in miami so have been hoping for a quiet week. well. whatever. another day in trumptopia. but alas, we can't tell the market what we want. so the game today is just don't make big mistakes and try and find interesting asymm
Novo Nordisk: 50% Drops Lead to Amazing GrowthFundamentals :
Take a look at NVO in 1999-2000, 2003, 2008, 2016 and June 20024-2025. Every time it dropped about 50%, that lead to a huge rally for years! NVO has secured contracts with Medicaid for their diabetes and other drugs. It is not going anywhere. It has fallen 50%. We either hold or buy
3/12/25 - $nvo - Hey now.. mr. mkt. i'll buy some3/12/25 :: VROCKSTAR :: NYSE:NVO
Hey now.. mr. mkt. i'll buy some
- i'm the first to tell you, i think pharma is rotton to the core
- but let's play the game here, emotions r a PnL killa
- sub 20x PE for 20-30% GROWTH?
- 4%+ cash yields
- EU's biggest co (and btw that's great orthogonal exposure
We are flipping resistance into support?Hey traders! 📈
Looking at these chart.
It seems like we broke resistance and might be consolidating above it.
Classic retest or fakeout? 🤔
What do you guys think, are we gearing up for a move toward TP1, or do we have the momentum to push straight to TP2?
RSI is cooling off, which looks more like
I am cautiously calling the bottom on NVOIt might be a bit early to call this a bottom, especially given the unpredictable market, but I’m noticing a few key signals aligning:
The 8/21 curl following a double bottom
A break above the 50-day SMA occurring on a red day like today
Momentum shifting positive and being released from a squ
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOVOB/N is featured.
Related stocks
Frequently Asked Questions
The current price of NOVOB/N is 1,300.00 MXN — it has decreased by −3.22% in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange NOVO NORDISK A/S stocks are traded under the ticker NOVOB/N.
NOVOB/N stock has fallen by −30.89% compared to the previous week, the month change is a −30.89% fall, over the last year NOVO NORDISK A/S has showed a −37.30% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOVOB/N price has a max estimate of 3,491.62 MXN and a min estimate of 1,229.66 MXN. Watch NOVOB/N chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOVOB/N stock is 2.56% volatile and has beta coefficient of 1.43. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of 5.74 T, it has decreased by −11.03% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NOVOB/N earnings for the last quarter are 18.29 MXN per share, whereas the estimation was 17.25 MXN resulting in a 6.08% surprise. The estimated earnings for the next quarter are 18.26 MXN per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to 247.24 B MXN, despite the estimated figure of 231.24 B MXN. In the next quarter, revenue is expected to reach 233.24 B MXN.
NOVOB/N net income for the last quarter is 81.46 B MXN, while the quarter before that showed 80.28 B MXN of net income which accounts for 1.47% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 16, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is 431.53 B MXN, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOVOB/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.